The rising global prevalence of glaucoma and associated risk factors such as high myopia, diabetes, eye surgery or injury, high blood pressure, increased use of corticosteroids, and a family history of glaucoma are expected to provide favourable future growth opportunities for acetazolamide drug manufacturers. Acetazolamide, when taken as a daily sustained release capsule, has a significant pressure-lowering impact that lasts at least 23 hours. Acetazolamide treatment lowers ocular pressure, which helps to prevent damage to the eyes. Acetazolamide lowers ocular pressure by inhibiting the function of an enzyme called carbonic anhydrase, which reduces the quantity of fluid secreted in the front region of the eye.
Read More:
https://bloggerstrive.blogspot.com/2022/03/extended-application-of-acetazolamide.html
Click here for Acetazolamide Market Report:
https://www.coherentmarketinsights.com/market-insight/acetazolamide-market-2396
Click here for Acetazolamide Market Press Release:
